摘要
目的探讨齐拉西酮与利培酮治疗精神分裂症患者的临床疗效和安全性。方法将79例精神分裂症患者随机分为两组，齐拉西酮组39例，口服齐拉西酮治疗，利培酮组40例，口服利培酮治疗，观察8周。于治疗前及治疗第2周、4周、8周末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降（P〈0．05或0．01），同期两组评分比较差异均无显著性（P〉0．05）；治疗8周末，齐拉西酮组有效率89．8％，利培酮组为90．0％，两组比较差异无显著性（x2=0．18，P〉0．05）。两组不良反应均轻微，齐拉西酮组锥体外系反应及内分泌方面不良反应发生率显著低于利培酮组（P〈0．01），其他不良反应发生率两组比较差异均无显著性（P〉0．05）。结论齐拉西酮与利培酮治疗精神分裂症疗效显著且相当，但齐拉西酮引起锥体外系反应及内分泌方面不良反应发生率低，安全性更高、依从性更好。
Objective To explore clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia. Methods Seventy-nine patients with schizophrenia were randomly divided into ziprasi- done group （n=39） took orally ziprasidone and risperidone group （n=40） did risperidone for 8 weeks. Ef- ficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） t baseline and at the end of the 2nd 4th and 8th week and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Re- sults After treatment the total and each factor scores of the PANSS of both groups lowered significantly compared with pretreatment （P〈0.05 or 0.01） , there were no significant differences in contemporaneous group comparisons （P〉0.05） ; at the end of the 8th week effective rate was respectively 89.98% in ziprasi- done and 90.0% in risperidone group, which showed no significant difference （Z2 =0.18, P〉0.05）. Ad- verse reactions of both groups were mild, incidences of extrapyramidal and endocrine adverse reactions were significantly lower in ziprasidone than risperidone group （P〈0.01）, there were no significant differ- ences in other adverse reactions （P〉0.05）. Conclusion Ziprasidone and risperidone have an evident and equivalent effect in the treatment of schizophrenia, but the former has lower incidences of extrapyramidal and endocrine adverse reactions, higher safety and better compliance.
出处
《临床心身疾病杂志》
CAS
2013年第1期43-44,61,共3页
Journal of Clinical Psychosomatic Diseases
